October 17, 2006 -- InterMune has found a partner in Roche for its protease inhibitor aimed at hepatitis C. To get the drug, Roche paid a princely sum for a drug that has yet to enter clinical trials: $60 million upfront and another $470 million in milestones. Roche will also underwrite two-thirds of the development costs. InterMune now joins Vertex and Schering-Plough in the race to develop a protease inhibitor for hepatitis C. We look at the deal and the competitive landscape...
